480 related articles for article (PubMed ID: 28841909)
21. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
[TBL] [Abstract][Full Text] [Related]
22. Long-Term Disease Control After locoregional Pelvic Chemoradiation in Patients with Advanced Anal Squamous Cell Carcinoma.
Grave A; Blanc J; De Bari B; Pernot M; Boulbair F; Noirclerc M; Vienot A; Kim S; Borg C; Boustani J
Front Oncol; 2022; 12():918271. PubMed ID: 35936677
[TBL] [Abstract][Full Text] [Related]
23. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel, cisplatin and 5-fluorouracil induction chemotherapy followed by chemoradiotherapy or chemoradiotherapy alone in stage III-IV unresectable head and neck cancer: Results of a randomized phase II study.
Takácsi-Nagy Z; Hitre E; Remenár É; Oberna F; Polgár C; Major T; Gödény M; Fodor J; Kásler M
Strahlenther Onkol; 2015 Aug; 191(8):635-41. PubMed ID: 25782685
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of chemoselection with docetaxel plus cisplatin and 5-fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer.
Yokota T; Kato K; Hamamoto Y; Tsubosa Y; Ogawa H; Ito Y; Hara H; Ura T; Kojima T; Chin K; Hironaka S; Kii T; Kojima Y; Akutsu Y; Matsushita H; Kawakami K; Mori K; Nagai Y; Asami C; Kitagawa Y
Br J Cancer; 2016 Nov; 115(11):1328-1334. PubMed ID: 27811857
[TBL] [Abstract][Full Text] [Related]
26. Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE).
Terada M; Hara H; Daiko H; Mizusawa J; Kadota T; Hori K; Ogawa H; Ogata T; Sakanaka K; Sakamoto T; Kato K; Kitagawa Y
Jpn J Clin Oncol; 2019 Dec; 49(11):1055-1060. PubMed ID: 31411696
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
[TBL] [Abstract][Full Text] [Related]
28. The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.
Eng C; Chang GJ; You YN; Das P; Rodriguez-Bigas M; Xing Y; Vauthey JN; Rogers JE; Ohinata A; Pathak P; Sethi S; Phillips JK; Crane CH; Wolff RA
Oncotarget; 2014 Nov; 5(22):11133-42. PubMed ID: 25373735
[TBL] [Abstract][Full Text] [Related]
29. [A case of advanced esophageal cancer with liver metastases: efficacy of combination therapy of docetaxel/cisplatin/5-FU].
Ehara K; Tsutsumi K; Kinoshita Y; Ueno M; Mine S; Udagawa H
Gan To Kagaku Ryoho; 2008 Aug; 35(8):1375-8. PubMed ID: 18701852
[TBL] [Abstract][Full Text] [Related]
30. Three cytotoxic drugs combined with pelvic radiation and as maintenance chemotherapy for patients with squamous cell carcinoma of the anus (SCCA): long-term follow-up of a phase II pilot study using 5-fluorouracil, mitomycin C and cisplatin.
Sebag-Montefiore D; Meadows HM; Cunningham D; Plowman PN; Hurman DC; Davidson N; Grieve R; Levine E; Glynne-Jones R
Radiother Oncol; 2012 Aug; 104(2):155-60. PubMed ID: 22857859
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer.
Yokota T; Hatooka S; Ura T; Abe T; Takahari D; Shitara K; Nomura M; Kondo C; Mizota A; Yatabe Y; Shinoda M; Muro K
Anticancer Res; 2011 Oct; 31(10):3535-41. PubMed ID: 21965775
[TBL] [Abstract][Full Text] [Related]
32. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.
Vermorken JB; Stöhlmacher-Williams J; Davidenko I; Licitra L; Winquist E; Villanueva C; Foa P; Rottey S; Skladowski K; Tahara M; Pai VR; Faivre S; Blajman CR; Forastiere AA; Stein BN; Oliner KS; Pan Z; Bach BA;
Lancet Oncol; 2013 Jul; 14(8):697-710. PubMed ID: 23746666
[TBL] [Abstract][Full Text] [Related]
33. Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients.
Cho BC; Ahn JB; Seong J; Roh JK; Kim JH; Chung HC; Sohn JH; Kim NK
BMC Cancer; 2008 Jan; 8():8. PubMed ID: 18194582
[TBL] [Abstract][Full Text] [Related]
34. A Pilot Trial of S-1 and Paclitaxel in Unresectable or Postoperative Recurrent Esophageal Squamous Cell Carcinoma Pretreated by Fluorouracil, Cisplatin, and Docetaxel Chemotherapy.
Nakajima Y; Kawada K; Tokairin Y; Hoshino A; Okada T; Kawano T
Dig Surg; 2018; 35(2):131-137. PubMed ID: 28554183
[TBL] [Abstract][Full Text] [Related]
35. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
36. Prognostic role of HPV integration status and molecular profile in advanced anal carcinoma: An ancillary study to the epitopes-HPV02 trial.
Debernardi A; Meurisse A; Prétet JL; Guenat D; Monnien F; Spehner L; Vienot A; Roncarati P; André T; Abramowitz L; Molimard C; Mougin C; Herfs M; Kim S; Borg C
Front Oncol; 2022; 12():941676. PubMed ID: 36313663
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
[TBL] [Abstract][Full Text] [Related]
38. A phase II evaluation of a 3-hour infusion of paclitaxel, cisplatin, and 5-fluorouracil in patients with advanced or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group study 0007.
Worden FP; Moon J; Samlowski W; Clark JI; Dakhil SR; Williamson S; Urba SG; Ensley J; Hussain MH;
Cancer; 2006 Jul; 107(2):319-27. PubMed ID: 16779801
[TBL] [Abstract][Full Text] [Related]
39. Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma.
Kim S; Boustani J; Vernerey D; Vendrely V; Evesque L; Francois E; Quero L; Ghiringhelli F; de la Fouchardière C; Dahan L; Bouché O; Chibaudel B; Hajbi FE; Vernet C; Rebucci-Peixoto M; Feuersinger A; Maritaz C; Borg C
Front Oncol; 2022; 12():918499. PubMed ID: 36119522
[TBL] [Abstract][Full Text] [Related]
40. [Effects of radical radiotherapy combined with different regimens of chemotherapy on radiation intestinal injury in patients with non-metastatic anal squamous cell carcinoma].
Pang XL; Liu S; Liu YP; Chen HY; He F; Zheng J; Wan XB
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Nov; 24(11):977-983. PubMed ID: 34823298
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
